Searchable abstracts of presentations at key conferences in endocrinology

ea0073pep1.2 | Presented ePosters 1: Adrenal and Cardiovascular Endocrinology | ECE2021

Tildacerfont for the treatment of patients with classic congenital adrenal hyperplasia: results from a 12-week phase 2 clinical trial in adults with classic CAH

Auchus Richard , Merke Deborah , Ivy-Joan Madu , Nakhle Samer , Sarafoglou Kyriakie , Huang Michael , Moriarty David , Barnes Chris , Newfield Ron

BackgroundCongenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD) is an autosomal recessive disorder characterized by insufficient cortisol production resulting in excess adrenocorticotropic hormone (ACTH) and adrenal androgen production. Standard-of-care therapy with glucocorticoids (GC) is suboptimal due to the difficulty of balancing control of the ACTH-driven androgen excess against the serious long-term side effects associated...

ea0090p1 | Adrenal and Cardiovascular Endocrinology | ECE2023

Crinecerfont (NBI-74788), a Novel CRF1 Receptor Antagonist, Lowers Adrenal Androgens and Precursors in Adolescents with Classic Congenital Adrenal Hyperplasia

Newfield Ron , Sarafoglou Kyriakie , Fechner Patricia Y. , Nokoff Natalie J. , Auchus Richard , Vogiatzi Maria , Giri Nagdeep , Roberts Eiry , Sturgeon Julia , Chan Jean L. , Farber Robert

Introduction: Classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21OHD) is a rare autosomal recessive disorder characterized by deficiency of cortisol and oftentimes aldosterone, with elevated adrenocorticotropic hormone (ACTH) and steroid precursors that are shunted toward excess androgen production. A phase 2 study of adults with classic 21OHD demonstrated that crinecerfont–an oral, non-steroidal, selective corticotropin-releasing factor type...